Meral Beksac, MD, Ankara University, Ankara, Turkey, talks on improving the outcomes of patients with multiple myeloma, highlighting the importance of selecting the best frontline treatment regimen in patients with multiple myeloma. Dr Beksac explains that the initial treatment a patient receives will determine the maximum treatment response they are able to achieve. It is also important to carefully monitor patients for M protein and serum free light chain levels, as well as extramedullary disease and resistant clones. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.